97 results on '"Wedzicha, Jadwiga A"'
Search Results
2. Association of a polygenic risk score for chronic obstructive pulmonary disease with lung function across the lifespan
3. Mucus, microbiomes, and lung function decline in COPD
4. Coronary artery disease, COPD exacerbation and inflammation
5. RSV as a Cause of Exacerbations of COPD
6. Blood eosinophil counts in younger smokers from the Early COPD Development Partnership
7. Fibrinogen as a biomarker of cardiovascular risk in COPD
8. The economic and health burden of COPD in the Middle East: forecasting through 2050
9. COPD Assessment Test (CAT) Score according to the presence/absence of accelerated lung function decline in young adult smokers with normal FEV1
10. Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET Clinical Research Collaboration
11. Dose response of icenticaftor in patients with COPD and chronic bronchitis on triple inhaled therapy
12. An estimate of the European prevalence of COPD in 2050
13. Prevalence and characteristics of asthma with fixed airflow obstruction:a CADSET European multi-cohort collaboration
14. Update on CADSET (Chronic Airway Disease Early Stratification) Clinical Research Collaboration
15. COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
16. Relationship of cardiac biomarkers in COPD to exacerbation and hyperinflation
17. Spirometric phenotypes from early childhood to young adulthood – A CADSET (Chronic Airway Disease Early Stratification) study
18. Collating data from major European population studies – The CADSET (Chronic airway disease early stratification) clinical research collaboration
19. Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
20. Home-based exercise training(HET) post-hospitalisation for acute exacerbation of COPD(AECOPD) - a mixed-method systematic review
21. A CADSET WP4 transcriptomic analysis of Asthma and COPD overlap
22. Aortic stiffness in young smokers classified as chronic bronchitis: the British Lung Foundation (BLF) Early COPD cohort
23. Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
24. Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
25. The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
26. Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial
27. Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin
28. Regional analysis of COPD exacerbation rates in the DYNAGITO trial
29. Late Breaking Abstract - Blood eosinophil count and exacerbation history in COPD: pooled analysis of 24,103 patients
30. Effect of erdosteine in moderately severe COPD patients
31. Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study
32. Baseline symptom burden and dual bronchodilator response in the FLAME study
33. Impact of stable state symptoms on the future burden of COPD exacerbations
34. Human rhinovirus impairs macrophage innate immune responses to bacteria via the interferon pathway in COPD
35. Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis
36. Dual bronchodilator response according to bronchitis symptoms in the FLAME study
37. Volatile organic compound (VOC) analysis to differentiate between bacterial and viral respiratory infections in COPD
38. Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
39. Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study
40. Combined impact of smoking and early life exposures on adult lung function
41. Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study
42. Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study
43. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study
44. Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study
45. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine)
46. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease: a Cochrane review update
47. The relationship between blood eosinophils and bacterial load in COPD patients
48. Longitudinal changes in COPD patients in primary care
49. Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
50. Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.